摘要
支气管哮喘为慢性炎症性疾病,糖皮质激素(GCS)仍然为临床哮喘包括慢性哮喘和哮喘急性发作最有效的治疗药物。吸入型糖皮质激素(ICS)可考虑用作慢性持续性哮喘的一线治疗。ICS联合长效b2受体激动剂(LABA)控制哮喘的效果优于单纯增加ICS剂量。本文阐述ICS和ICS/LABA在轻、中度持续性哮喘治疗中的临床地位,以及哮喘急性发作时全身用GCS的效果。
The bronchial asthma is viewed as a chronic inflammatory disease. Corticosteroids remain the most effective therapy for asthma, both in chronic asthma and acute exacerbation. The inhaled corticosteroids （ICS） may be considered as first-line therapy in patients with chronic persistent asthma. ICS in addition of long-acting β2 agonists （LABA） gives better control of asthma than increasing the dose of ICS alone. This paper described the place of ICS and ICS/LABA in the management of mild to moderate persistent sever asthma, and the use of systemic corticosteroids in acute exacerbation.
出处
《世界临床药物》
CAS
2009年第1期1-6,共6页
World Clinical Drug
